CHICAGO--(BUSINESS WIRE)--In a Phase III pilot dose-ranging study of patients hospitalized with acute heart failure syndrome and renal impairment treatment with rolofylline, an investigational adenosine A1 receptor antagonist in development by Merck & Co., Inc., administered with intravenous (IV) loop diuretics was associated with improved dyspnea (shortness of breath) and preserved renal function compared to treatment with placebo and IV diuretics. In addition, in a post-hoc analysis, treatment with rolofylline was associated with a trend towards reduced 60-day mortality or hospital readmission for cardiovascular or renal causes. These results were presented today as a late-breaking abstract at the Annual Scientific Session of the American College of Cardiology.
